Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 36

Sort by

Sort Order Select

Journal Articles

Donor-derived CD7 CAR T cells for pediatric and adult relapsed/refractory T-ALL/LBL: a phase 2 trial

Blood (2025) 146 (23): 2745–2757.

https://doi.org/10.1182/blood.2025029299

Published: 2025

Includes: Supplemental data

Journal Articles

Prospective phase I/II study of CD19-directed CAR-t therapy in relapsed/refractory central nervous system lymphoma: Clinical outcomes and safety profile

Danyang Li, Rui Liu, Zhonghua Fu, Fan Yang, Lixia Ma, Miaomiao Cao, Yuelu Guo, Biping Deng, Alex H. Zhang, Qinlong Zheng, Xiaoyan Ke, Kai Hu

Blood (2025) 146 (Supplement 1): 672.

https://doi.org/10.1182/blood-2025-672

Published: 2025

Journal Articles

Genomic heterogeneity and prognostic implications in CAR-t-treated relapsed/refractory primary CNS lymphoma

Miaomiao Cao, Hui Shi, Danyang Li, Rui Liu, Zhonghua Fu, Fan Yang, Lixia Ma, Yuelu Guo, Biping Deng, Alex H. Zhang, Qinlong Zheng, Xiaoyan Ke, Kai Hu

Blood (2025) 146 (Supplement 1): 5489.

https://doi.org/10.1182/blood-2025-5489

Published: 2025

Journal Articles

The ratio of post-infusion circulating PD-1+ CAR-T subsets to product PD-1+ CAR-T cells serves as a predictive biomarker for long-term disease control in CAR T-cell therapy for R/R B-cell lymphoma

Fan Yang, Rui Liu, Zhonghua Fu, Yuelu Guo, Lixia Ma, Miaomiao Cao, Biping Deng, Shilin Gan, Alex H. Zhang, Xiaoyan Ke, Kai Hu

Blood (2025) 146 (Supplement 1): 2377.

https://doi.org/10.1182/blood-2025-2377

Published: 2025

Journal Articles

CD7 chimeric antigen receptor T cells for relapsed/refractory T-cell lymphomas: Single-arm, open-label, phase I study

Fan Yang, Rui Liu, Yuelu Guo, Lixia Ma, Miaomiao Cao, Biping Deng, Haifeng Wu, Alex H. Zhang, Xiaoyan Ke, Kai Hu

Blood (2025) 146 (Supplement 1): 2368.

https://doi.org/10.1182/blood-2025-2368

Published: 2025

Journal Articles

CAR-t cell therapy in TP53-mutated CNS lymphoma: Overcoming a high-risk genetic barrier

Danyang Li, Rui Liu, Zhonghua Fu, Fan Yang, Lixia Ma, Miaomiao Cao, Yuelu Guo, Biping Deng, Alex H. Zhang, Qinlong Zheng, Xiaoyan Ke, Kai Hu

Blood (2025) 146 (Supplement 1): 3708.

https://doi.org/10.1182/blood-2025-3708

Published: 2025

Journal Articles

Impact of TP53 mutations on survival outcomes in the CAR-t era of large b-cell lymphoma

Rui Liu, Danyang Li, Zhonghua Fu, Fan Yang, Miaomiao Cao, Lixia Ma, Yuelu Guo, Alex H. Zhang, Biping Deng, Qinlong Zheng, Xiaoyan Ke, Kai Hu

Blood (2025) 146 (Supplement 1): 3706.

https://doi.org/10.1182/blood-2025-3706

Published: 2025

Journal Articles

Short-course glofitamab enables effective bridging to CAR-t therapy in B-NHL

Rui Liu, Zhonghua Fu, Fan Yang, Lixia Ma, Miaomiao Cao, Yuelu Guo, Danyang Li, Biping Deng, Qinlong Zheng, Alex H. Zhang, Xiaoyan Ke, Kai Hu

Blood (2025) 146 (Supplement 1): 7259.

https://doi.org/10.1182/blood-2025-7259

Published: 2025

Journal Articles

Transplantation in combination with CAR T-cell therapy for refractory/relapsed aggressive B-cell lymphoma after failure of CD19 CAR-T cell therapy

Fan Yang, Rui Liu, Yuelu Guo, Lixia Ma, Miaomiao Cao, Biping Deng, Haifeng Wu, Alex H. Zhang, Xiaoyan Ke, Kai Hu

Blood (2025) 146 (Supplement 1): 5484.

https://doi.org/10.1182/blood-2025-5484

Published: 2025

Journal Articles

Utilizing BTK Inhibitors for Maintenance and Long-Term Control Following CAR-T Cell Therapy in B-Cell Non-Hodgkin Lymphoma

Rui Liu, Fan Yang, Lixia Ma, Yuelu Guo, Zhonghua Fu, Biping Deng, Qinlong Zheng, Xiaoyan Ke, Kai Hu

Blood (2024) 144 (Supplement 1): 6183.

https://doi.org/10.1182/blood-2024-202415

Published: 2024

Journal Articles

Efficacy and Safety of BCMA-CAR-T Cell Therapy in Relapsed/Refractory Extramedullary Plasmacytoma: Exploring the Role of Consolidation Therapy

Lixia Ma, Rui Liu, Fan Yang, Yuelu Guo, Yimeng Dou, Biping Deng, Zhonghua Fu, Xiaoyan Ke, Kai Hu

Blood (2024) 144 (Supplement 1): 3387.

https://doi.org/10.1182/blood-2024-200523

Published: 2024

Journal Articles

Treatment Outcomes in Patients with R/R CNSL in the Era of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy

Fan Yang, Rui Liu, Zhonghua Fu, Yuelu Guo, Lixia Ma, Hui SHI, Biping Deng, Xiaoyan Ke, Kai Hu

Blood (2024) 144 (Supplement 1): 3079.

https://doi.org/10.1182/blood-2024-202286

Published: 2024

Journal Articles

Clinical Analysis of CAR-T Cell Therapy in Patients with Relapsed Acute B-Lymphoblastic Leukemia after Second Allogeneic Hematopoietic Stem Cell Transplantation

Hong Yan, Biyi Li, Ruyue Zheng, Yuehui Lin, Lihong An, Biping Deng, Chunrong Tong, Tong Wu, Defeng Zhao

Blood (2024) 144 (Supplement 1): 7214.

https://doi.org/10.1182/blood-2024-204694

Published: 2024

Journal Articles

Clinical Analysis of Sequential CAR-T Therapy Combined with Demethylating Agents and Personalized Targeted Drugs in 18 Elderly Patients with Relapsed/Refractory Acute B-Lymphoblastic Leukemia

Biyi Li, Hong Yan, Ruyue Zheng, Shuangyou Liu, Yuehui Lin, Lihong An, Biping Deng, Qinlong Zheng, Chunrong Tong, Tong Wu, Defeng Zhao

Blood (2024) 144 (Supplement 1): 7213.

https://doi.org/10.1182/blood-2024-204670

Published: 2024

Journal Articles

Impact of CD58 Mutations on CAR-T Cell Therapy in B-Cell Non-Hodgkin Lymphoma: Clinical Insights and Therapeutic Potential

Bian Wei, Rui Liu, Fan Yang, Lixia Ma, Yuelu Guo, Qinlong Zheng, Biping Deng, Zhonghua Fu, Xiaoyan Ke, Kai Hu

Blood (2024) 144 (Supplement 1): 6549.

https://doi.org/10.1182/blood-2024-206676

Published: 2024

Journal Articles

Clinical Analysis of CAR-T Cell Therapy in Patients with Acute B-Lymphoblastic Leukemia and Central Nervous System Infiltration

Hong Yan, Biyi Li, Ruyue Zheng, Yuehui Lin, Biping Deng, Chunrong Tong, Tong Wu, Defeng Zhao

Blood (2024) 144 (Supplement 1): 7215.

https://doi.org/10.1182/blood-2024-204742

Published: 2024

Journal Articles

Retrospective Comparison of the Roles of Tocilizumab and Siltuximab in the Management of Toxicity in CAR-T Cell Therapy for Relapsed/Refractory B-NHL

Rui Liu, Fan Yang, Lixia Ma, Yuelu Guo, Zhonghua Fu, Biping Deng, Chen Chen, Xiaoyan Ke, Kai Hu

Blood (2024) 144 (Supplement 1): 7247.

https://doi.org/10.1182/blood-2024-201274

Published: 2024

Journal Articles

Clinical Analysis of 15 Cases of Extramedullary Relapse of Acute B-Lymphoblastic Leukemia Post-Transplant Treated with CART Combined with Radiotherapy

Ruyue Zheng, Hong Yan, Biyi Li, Yuehui Lin, Shuangyou Liu, Lihong An, Biping Deng, Jun Zhang, Chunrong Tong, Tong Wu, Defeng Zhao

Blood (2024) 144 (Supplement 1): 7212.

https://doi.org/10.1182/blood-2024-204574

Published: 2024

Journal Articles

The Safety and Efficacy of CD33 CAR-T Therapy for RR AML after HSCT

Yuehui Lin, Defeng Zhao, Biping Deng, Dan Liu, Hong Yan, Biyi Li, Yu Xia, Ruyue Zheng, Tong Wu, Chunrong Tong

Blood (2024) 144 (Supplement 1): 3467.

https://doi.org/10.1182/blood-2024-207659

Published: 2024

Journal Articles

The Clinical Value of Prognostic Nutritional Index in CAR-T Therapy for Patients with Malignant Lymphoma

Na Zhang, Rui Liu, Fan Yang, Lixia Ma, Yuelu Guo, Zhonghua Fu, Haifeng Wu, Biping Deng, Xiaoyan Ke, Kai Hu

Blood (2024) 144 (Supplement 1): 1745.

https://doi.org/10.1182/blood-2024-202403

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Donor-derived CD7 CAR T cells for pediatric and adult relapsed/refractory T-ALL/LBL: a phase 2 trial

Prospective phase I/II study of CD19-directed CAR-t therapy in relapsed/refractory central nervous system lymphoma: Clinical outcomes and safety profile

Genomic heterogeneity and prognostic implications in CAR-t-treated relapsed/refractory primary CNS lymphoma

The ratio of post-infusion circulating PD-1+ CAR-T subsets to product PD-1+ CAR-T cells serves as a predictive biomarker for long-term disease control in CAR T-cell therapy for R/R B-cell lymphoma

CD7 chimeric antigen receptor T cells for relapsed/refractory T-cell lymphomas: Single-arm, open-label, phase I study

CAR-t cell therapy in TP53-mutated CNS lymphoma: Overcoming a high-risk genetic barrier

Impact of TP53 mutations on survival outcomes in the CAR-t era of large b-cell lymphoma

Short-course glofitamab enables effective bridging to CAR-t therapy in B-NHL

Transplantation in combination with CAR T-cell therapy for refractory/relapsed aggressive B-cell lymphoma after failure of CD19 CAR-T cell therapy

Utilizing BTK Inhibitors for Maintenance and Long-Term Control Following CAR-T Cell Therapy in B-Cell Non-Hodgkin Lymphoma

Efficacy and Safety of BCMA-CAR-T Cell Therapy in Relapsed/Refractory Extramedullary Plasmacytoma: Exploring the Role of Consolidation Therapy

Treatment Outcomes in Patients with R/R CNSL in the Era of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy

Clinical Analysis of CAR-T Cell Therapy in Patients with Relapsed Acute B-Lymphoblastic Leukemia after Second Allogeneic Hematopoietic Stem Cell Transplantation

Clinical Analysis of Sequential CAR-T Therapy Combined with Demethylating Agents and Personalized Targeted Drugs in 18 Elderly Patients with Relapsed/Refractory Acute B-Lymphoblastic Leukemia

Impact of CD58 Mutations on CAR-T Cell Therapy in B-Cell Non-Hodgkin Lymphoma: Clinical Insights and Therapeutic Potential

Clinical Analysis of CAR-T Cell Therapy in Patients with Acute B-Lymphoblastic Leukemia and Central Nervous System Infiltration

Retrospective Comparison of the Roles of Tocilizumab and Siltuximab in the Management of Toxicity in CAR-T Cell Therapy for Relapsed/Refractory B-NHL

Clinical Analysis of 15 Cases of Extramedullary Relapse of Acute B-Lymphoblastic Leukemia Post-Transplant Treated with CART Combined with Radiotherapy

The Safety and Efficacy of CD33 CAR-T Therapy for RR AML after HSCT

The Clinical Value of Prognostic Nutritional Index in CAR-T Therapy for Patients with Malignant Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only